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LETTER TO THE EDITOR
Interleukin-10-de®cient Mice Are Less Susceptible to the
Induction of Alopecia Areata
To the Editor:
Interleukin (IL)-10 is widely accepted to exert an immunosup-
pressive action on T helper (Th)-1 cell-mediated skin diseases such
as psoriasis vulgaris or allergic contact dermatitis, and is involved in
the induction of tolerance in T cell mediated autoimmune diseases.
Hence, IL-10 may be a candidate for novel treatment modalities in
T cell mediated diseases where current therapeutic approaches are
insuf®cient or unsuccessful.
Alopecia areata (AA) is regarded as a T cell mediated
autoimmune disease of the hair follicle, expressing the Th-1
cytokines IL-1b, IL-2, and interferon (IFN)-g (Hoffmann et al,
1994). In scalp samples of AA patients successfully treated with
diphenylcyclopropenone, the Th-1 cytokines are downregulated
and the Th-2 cytokines, IL-10 and transforming growth factor
(TGF)-b, are upregulated (Hoffmann et al, 1994), pointing
towards an involvement of IL-10 in the process of immuno-
suppression with subsequent hair regrowth after treatment of
AA with a contact sensitizer. Because current treatments of AA
show only limited success we became interested in the question
whether the application of IL-10 offers a new treatment option
in AA, as demonstrated in other T cell mediated diseases. To
lay the foundations for answering this question, it was necessary
to investigate the role of IL-10 in an in-vivo model of AA.
C3H/HeJ mice spontaneously develop an AA-like disease and
AA can be induced in unaffected C3H/HeJ mice or other
histocompatible strains by grafting full thickness, lesional AA skin
from AA-affected C3H/HeJ mice (McElwee et al, 1998). To
investigate the in¯uence of IL-10 on the development of AA, onset
and severity of AA were evaluated in IL-10-de®cient mice after
transplantation of AA-affected skin. A rapid onset and extensive
degree of the disease in IL-10-de®cient mice would have supported
our hypothesis of an immunosuppressive action of IL-10 in the
development of AA and could have been indicative for IL-10 as a
therapeutic option in AA.
AA-affected skin was grafted on to 20 C3Bir.129P2(B6)-IL-
10tm1Cgn/Lt mice (further referred to as IL-10±/± mice) and on
to 20 unaffected C3H/HeJ mice (further also referred to as IL-
10+/+ mice) using procedures as described previously (McElwee
et al, 1998). After 17 wk, the extent of hair loss was assessed
semiquantitatively according to the following scoring system: no
hair loss, limited hair loss (< 30% of total surface area affected),
extensive hair loss (> 30% of total surface area affected). One of
the IL-10±/± mice died 12 wk after grafting without developing
hair loss. Of the remaining 19 IL-10±/± mice, seven developed
limited hair loss after a mean of 13 wk (6 1.7 SD) and 12
developed no hair loss. Extensive hair loss was not observed in
any IL-10±/± mouse. By contrast, 19 of 20 IL-10+/+ mice
developed hair loss within a mean of 6.6 wk (6 3.1 SD), 16
showing extensive hair loss and three limited hair loss. Thus
there is a highly signi®cant difference in the number of mice,
developing hair loss after grafting, between IL-10±/± and IL-
10+/+ mice (p = 0.01; Mann±Whitney U test), indicating, that
IL-10±/± mice are relatively resistant to the experimental
induction of AA. These results were unexpected because
other T cell mediated autoimmune diseases, such as in¯amma-
tory bowel disease, experimental autoimmune encephalomyelitis
and T cell mediated skin diseases such as contact-hypersensitiv-
ity responses, have been shown to be exaggerated in IL-10±/±
mice (Moore et al, 2001). Our results, however, suggest that
IL-10 may exert an immunostimulatory effect in AA of C3H/
HeJ mice. In fact, an immunostimulatory role of IL-10 has
been also shown in other autoimmune diseases: Transgenic
expression of IL-10 in pancreatic islet A cells accelerates
autoimmune insulinitis and diabetes in non-obese diabetic
mice (Moritani et al, 1994). The authors concluded, that IL-
10 secreted in situ enhanced cell-mediated autoimmune diabetes.
Balasa et al (1998) have shown that IL-10 contributes to the
early phase of development of autoimmune diabetes via a CD8+
T cell pathway. Furthermore, IL-10-de®cient mice are less
susceptible to anti-type II collagen antibody induced arthritis
(Johansson et al, 2001).
To make sure that the relative AA-resistance of IL-10±/± mice
was not a secondary phenomenon due to a downregulation of
proin¯ammatory cells or cytokines, or upregulation of anti-
in¯ammatory cytokines, ¯ow cytometry analyses of skin-in®ltrating
leukocytes (SkIL) and skin draining lymph node cells (LNC) was
performed for the expression of CD4, CD8, monocytes, dendritic
cells, IL-2, IL-6, IL-10, IL-12, TGF-b, tumor necrosis factor
(TNF)-a and IFN-g as described elsewhere (ZoÈller et al, 2002).
The results of ¯uorescence-activated cell sorter analysis of SkIL are
shown in Fig 1(a,b). The data show that the percentage of
monocytes and dendritic cells was increased in IL-10±/± mice
independent of AA development. Yet, neither CD8+ nor CD4+
cell frequencies were signi®cantly reduced. Thus, the relative AA-
resistance of IL-10±/± mice is apparently not due to a lack of
in¯ammatory cell recruitment.
The only signi®cant difference in cytokine expression between
IL-10±/± and IL-10+/+ mice was seen in the percentage of IL-6
expressing cells, which was signi®cantly higher (p = 0.01; Student's
t test) in transplanted IL-10+/+as compared with IL-10±/± mice.
Only background levels of IL-10 were seen in IL-10±/± mice,
which implies that no signi®cant percentage of IL-10 expressing
leukocytes derived from the grafted AA-affected IL-10+/+ skin had
in®ltrated and proliferated in the host skin. No signi®cant
differences between IL-10±/± mice and controls were observed in
the levels of the proin¯ammatory and in¯ammatory cytokines IL-2,
IFN-g, TNF-a, and IL-12 expressed by SkIL. These results were
unexpected because we had anticipated an excessively high reaction
of the Th-1 cytokines IL-12 and IFN-g in the absence of IL-10,
that are apparently not built up in the dermal environment or a Th-
1 effector cells do not reach the skin.
Hence, we became interested to see the cytokine expression
pro®le in draining LNC (Fig 1c). We found that expression of IL-
6, which was low in skin in®ltrating leukocytes of IL-10±/±, did not
differ in draining LNC of IL-10±/± and IL-10+/+ mice. Therefore,
we consider the low level of IL-6 in the skin of AA-grafted IL-
10±/± mice as a secondary phenomenon due to the overall low level
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Figure 1. Increased levels of IFN-g, TNF-a, and TGF-b in draining LNC of IL-10±/± mice. IL-10±/± mice were compared by ¯ow cytometry
with IL-10+/+ mice without skin grafting and with and without AA-development after grafting AA-affected skin. Analyses of SkIL (A), SkIL cytokine
expression (B), and skin draining LNC cytokine expression (C) are shown. SkIL showed an increased percentage of macrophages and dendritic cells in
IL-10±/± mice without grafting and in those developing AA after grafting (A). The percentage of IL-6 expressing cells was signi®cantly lower in SkIL of
grafted IL-10±/± mice as compared with IL-10+/+ mice (B), but in draining LNC of IL-10±/± and IL-10+/+ mice IL-6 did not differ. IFN-g, TNF-a,
and TGF-b were upregulated in draining LNC of IL-10±/± mice as compared with IL-10+/+ mice (C). Arrows indicate signi®cant increased or
decreased frequency of expression (p < 0.01) as compared with IL-10+/+ mice by Student's t test. Abbreviations: Mo, monocytes; DC, dendritic cells.
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of in¯ammation in the skin of AA-transplanted IL-10±/± mice.
Concerning the expected upregulation of Th-1 cytokines, we
found that IFN-g was indeed signi®cantly upregulated in draining
LNC of IL-10±/± as compared with IL-10+/+ mice, which in turn
accounted for the expression of the proin¯ammatory cytokine
TNF-a. The anti-in¯ammatory cytokine TGF-b, however, was
likewise upregulated in LNC of IL-10±/± mice, which can be taken
as an exaggerated compensation for the IL-10 de®ciency. The
immunosuppressive action of TGF-b might inhibit activated
leukocytes to reach affected skin areas. Whether such a dysregula-
tion of response is in fact responsible for AA resistance of IL-10±/±
mice remains to be explored.
Alternatively, AA resistance of IL-10±/± mice might be explained
by a disease promoting action of IL-10. A disease promoting action
of IL-10 in turn would suggest a contribution of Th-2 cells to AA
pathogenesis. This assumption is supported by the high levels of IL-
10 and TGF-b in AA-affected control mice. Hence, our results are
in line with the observation that by the cytokine expression pro®le
of SkIL, AA cannot be de®ned as either a classical Th-1 or Th-2
reaction (ZoÈller et al, 2002). Analogous observations have been
made in the induction of experimental autoimmune myasthenia
gravis: IL-10±/± mice were less susceptible to experimental
autoimmune myasthenia gravis and an involvement of both Th-1
and Th-2 cells could be demonstrated (Poussin et al, 2000). The
high expression of hair follicle speci®c autoantibodies in human and
rodent AA circumstantially con®rm Th-2 cell activity (McElwee et
al, 1999).
Interestingly, several factors regarded as stimulatory in AA
pathogenesis, are upregulated in the skin of IL-10±/± mice, e.g.,
dendritic cells and monocytes. A comparable observation of the
presence of disease-promoting factors but absence of the disease has
been made in the induction of airway hyperresponsiveness in IL-
10±/± mice (Justice et al, 2001). This suggests an important
pathogenetic role of IL-10 in the development of some T cell
mediated diseases. Chen and Zlotnik (1991) showed that CD8+ T
cells cultured in IL-2 + IL-10 exhibit higher cytotoxic activity than
CD8+ T cells grown in IL-2 alone. Furthermore, IL-10 has been
shown to stimulate the differentiation of cytotoxic T cells (Suda et
al, 1990). CD8+ cells are suspected to affect directly the hair follicle
in AA (McElwee et al, 1996), probably by acting as cytotoxic T
cells (Bodemer et al, 2000). Thus IL-10 may be involved in the
pathogenesis of AA by promoting the cytotoxic capacity of CD8+
cells.
In conclusion we have shown that IL-10±/± mice are less
susceptible to AA induction suggesting either a proin¯ammatory
role of IL-10 in the pathogenesis of AA or a compensation for the
IL-10-de®ciency. Though these alternatives require further explor-
ation, our results clearly indicate that IL-10 will not be a
therapeutic option for AA.
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